MAPT and Alzheimer disease: Treated animals have sustained hyperglycaemia without any overt illness (Murtishaw et al., 2018); they exhibit learning and memory deficits, increased tau phosphorylation and increased neuroinflammation similar to the pathological changes observed in AD (Murtishaw et al., 2018).